Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma Group (MREO) Enterprise Value: 2020-2025

Historic Enterprise Value for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to $279.0 million.

  • Mereo BioPharma Group's Enterprise Value fell 49.43% to $279.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.6 million, marking a year-over-year decrease of 74.71%. This contributed to the annual value of $307.0 million for FY2024, which is 15.51% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Enterprise Value stood at $279.0 million for Q3 2025, which was up 34.17% from $208.0 million recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year Enterprise Value high stood at $551.8 million for Q3 2024, and its period low was $3.9 million during Q4 2021.
  • For the 3-year period, Mereo BioPharma Group's Enterprise Value averaged around $302.7 million, with its median value being $295.3 million (2025).
  • As far as peak fluctuations go, Mereo BioPharma Group's Enterprise Value crashed by 98.02% in 2021, and later surged by 2,130.91% in 2023.
  • Over the past 5 years, Mereo BioPharma Group's Enterprise Value (Quarterly) stood at $3.9 million in 2021, then surged by 400.44% to $19.6 million in 2022, then surged by 1,758.41% to $363.4 million in 2023, then decreased by 15.51% to $307.0 million in 2024, then crashed by 49.43% to $279.0 million in 2025.
  • Its Enterprise Value stands at $279.0 million for Q3 2025, versus $208.0 million for Q2 2025 and $295.3 million for Q1 2025.